248 related articles for article (PubMed ID: 28574754)
1. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 66 Canadian hospitals: A 2016 follow-up study.
Roland C; Caron N; Bussières JF
J Occup Environ Hyg; 2017 Aug; 14(8):661-669. PubMed ID: 28574754
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals.
Poupeau C; Tanguay C; Caron NJ; Bussières JF
J Oncol Pharm Pract; 2018 Jan; 24(1):9-17. PubMed ID: 27799608
[TBL] [Abstract][Full Text] [Related]
3. Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals.
Merger D; Tanguay C; Langlois E; Lefebvre M; Bussières JF
Int Arch Occup Environ Health; 2014 Apr; 87(3):307-13. PubMed ID: 23471647
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study.
Berruyer M; Tanguay C; Caron NJ; Lefebvre M; Bussières JF
J Occup Environ Hyg; 2015; 12(2):87-94. PubMed ID: 25105559
[TBL] [Abstract][Full Text] [Related]
5. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device.
Guillemette A; Langlois H; Voisine M; Merger D; Therrien R; Mercier G; Lebel D; Bussières JF
J Oncol Pharm Pract; 2014 Dec; 20(6):426-32. PubMed ID: 24395542
[TBL] [Abstract][Full Text] [Related]
6. Surface contamination with ten antineoplastic drugs in 83 Canadian centers.
Chauchat L; Tanguay C; Caron NJ; Gagné S; Labrèche F; Bussières JF
J Oncol Pharm Pract; 2019 Jul; 25(5):1089-1098. PubMed ID: 29726786
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of surface contamination in a hospital hematology--oncology pharmacy.
Touzin K; Bussières JF; Langlois E; Lefebvre M
J Oncol Pharm Pract; 2009 Mar; 15(1):53-61. PubMed ID: 18772214
[TBL] [Abstract][Full Text] [Related]
8. Environmental contamination with methotrexate in Canadian community pharmacies.
Merger D; Tanguay C; Langlois É; Lefebvre M; Bussières JF
J Am Pharm Assoc (2003); 2013; 53(4):423-6. PubMed ID: 23892817
[TBL] [Abstract][Full Text] [Related]
9. Environmental Contamination with Cyclophosphamide, Ifosfamide, and Methotrexate: A Study of 51 Canadian Centres.
Janes A; Tanguay C; Caron NJ; Bussières JF
Can J Hosp Pharm; 2015; 68(4):279-89. PubMed ID: 26327701
[TBL] [Abstract][Full Text] [Related]
10. Cross-sectional evaluation of surface contamination with 9 antineoplastic drugs in 93 Canadian healthcare centers: 2019 results.
Palamini M; Gagné S; Caron N; Bussières JF
J Oncol Pharm Pract; 2020 Dec; 26(8):1921-1930. PubMed ID: 32114883
[TBL] [Abstract][Full Text] [Related]
11. Quantification of healthcare workers' exposure to cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil by 24-h urine assay: A descriptive pilot study.
Palamini M; Dufour A; Therrien R; Delisle JF; Mercier G; Gagné S; Caron N; Bussières JF
J Oncol Pharm Pract; 2020 Dec; 26(8):1864-1870. PubMed ID: 32138611
[TBL] [Abstract][Full Text] [Related]
12. Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers.
Delafoy C; Roussy C; Hudon AF; Cirtiu CM; Caron N; Bussières JF; Tanguay C
J Oncol Pharm Pract; 2023 Mar; 29(2):338-347. PubMed ID: 35018847
[TBL] [Abstract][Full Text] [Related]
13. Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 124 centers.
Pinet E; Cirtiu CM; Caron N; Bussières JF; Tanguay C
J Oncol Pharm Pract; 2024 Jan; 30(1):19-29. PubMed ID: 37021440
[TBL] [Abstract][Full Text] [Related]
14. Surface contamination with nine antineoplastic drugs in 109 canadian centers; 10 years of a monitoring program.
Chabut C; Tanguay C; Gagné S; Caron N; Bussières JF
J Oncol Pharm Pract; 2022 Mar; 28(2):343-352. PubMed ID: 33567975
[TBL] [Abstract][Full Text] [Related]
15. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States.
Connor TH; Anderson RW; Sessink PJ; Broadfield L; Power LA
Am J Health Syst Pharm; 1999 Jul; 56(14):1427-32. PubMed ID: 10428450
[TBL] [Abstract][Full Text] [Related]
16. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers.
Sessink PJ; Boer KA; Scheefhals AP; Anzion RB; Bos RP
Int Arch Occup Environ Health; 1992; 64(2):105-12. PubMed ID: 1399019
[TBL] [Abstract][Full Text] [Related]
17. Occupational exposure to antineoplastic drugs in hospital environments: potential risk associated with contact with cyclophosphamide- and ifosfamide-contaminated surfaces.
Mucci N; Dugheri S; Farioli A; Garzaro G; Rapisarda V; Campagna M; Bonari A; Arcangeli G
Med Pr; 2020 Sep; 71(5):519-529. PubMed ID: 32667290
[TBL] [Abstract][Full Text] [Related]
18. External contamination of antineoplastic drug containers from a Canadian wholesaler.
Hilliquin D; Bussières JF
J Oncol Pharm Pract; 2020 Mar; 26(2):423-427. PubMed ID: 31446868
[TBL] [Abstract][Full Text] [Related]
19. Occupational exposure to antineoplastic drugs: what about hospital sanitation personnel?
Labrèche F; Ouellet C; Roberge B; Caron NJ; Yennek A; Bussières JF
Int Arch Occup Environ Health; 2021 Nov; 94(8):1877-1888. PubMed ID: 34410477
[TBL] [Abstract][Full Text] [Related]
20. Cross-Sectional Evaluation of Surface Contamination with Antineoplastic Drugs in Canadian Health Care Centres.
Hilliquin D; Tanguay C; Gagné S; Caron NJ; Bussières JF
Can J Hosp Pharm; 2019; 72(5):377-384. PubMed ID: 31692608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
